The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial
Abstract
OBJECTIVE: Currently there is no approved pharmacotherapy for amphetamine dependence. Recent human laboratory studies have demonstrated that naltrexone modulates some of the reinforcing effects of amphetamine. The aim of this study was to investigate the efficacy of naltrexone in comparison with placebo in reducing relapse to amphetamine use in amphetamine-dependent patients. METHOD: Eighty patients who met DSM-IV criteria for amphetamine dependence were randomized to 12 weeks of double-blind naltrexone (50 mg) or placebo treatment. Patients visited the clinic twice weekly to receive medication and relapse prevention therapy and leave urine samples, which were analyzed for drug toxicology and for assessing adherence to medication via detection of naltrexone's metabolite (6-beta-naltrexol). The main outcome measure was abstinence from amphetamine use, as indicated by the total number of negative amphetamine urine samples during 12 weeks of treatment. All missing urine samples were defined for the analysis as positive for amphetamine. RESULTS: Overall, 55 patients (68.8%) completed the trial. The intention-to-treat analysis showed that the naltrexone group had a significantly higher number of amphetamine-negative urine samples compared with the placebo group. Survival analyses showed that the treatment groups differed in rate of continuous abstinence, in both the intention-to-treat and completer samples, in favor of naltrexone treatment. There was a significant reduction in craving levels and self-reported consumption of amphetamine in the naltrexone group compared with the placebo group. Treatment with naltrexone was well tolerated in this sample. CONCLUSIONS: This trial demonstrated the efficacy of naltrexone in reducing amphetamine use in amphetamine-dependent individuals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A randomized controlled trial of naltrexone (50mg/d) for amphetamine use disorder showed significantly greater reductions in craving ratings compared to placebo (50).”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [50]
In the citing paper
“Significantly greater reduction in craving”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Jayaram- Lindström et al., 2008
Citations
Cites
1 retracted
Treatment for amphetamine dependence and abuse
Srisurapanont, M., Jarusuraisin, N., & Kittirattanapaiboon, P. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003022 · Cited by 81
RetractedThe fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222
A psychomotor stimulant theory of addiction.
Wise, R. A., & Bozarth, M. A. (1987) · Psychological Review · doi:10.1037/0033-295x.94.4.469 · Cited by 2,747
Central Catecholamine Neuron Systems: Anatomy and Physiology of the Dopamine Systems
Moore, R. Y., & Bloom, F. E. (1978) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.01.030178.001021 · Cited by 926
Measuring Alcohol Consumption: Psychosocial and Biochemical Methods
(1992) · Humana Press eBooks · doi:10.1007/978-1-4612-0357-5 · Cited by 504
The development of a cocaine craving questionnaire
Tiffany, S. T., Singleton, E., Haertzen, C. A., & Henningfield, J. E. (1993) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(93)90042-o · Cited by 435
Neurobiology of addiction: treatment and public policy ramifications
Dackis, C., & O'Brien, C. (2005) · Nature Neuroscience · doi:10.1038/nn1105-1431 · Cited by 267
Naltrexone-induced alterations in human ethanol intoxication
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.10.1463 · Cited by 254 · cited 1×
“It has been established (13, 19, 20) that the therapeutic effect of naltrexone does not result from any nonspecific effect, such as a pharmacokinetic interaction.”
BackgroundKing, A. C., Volpicelli, J. R., Frazer, A., & O'Brien, C. P. (1997) · Psychopharmacology · doi:10.1007/s002130050156 · Cited by 227
Croop, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830240090013 · Cited by 211
Research works printed but not linked: 5
- United Nations Office on Drugs and Crime, 2005, Drug Report
- Swedish Council for Information on Alcohol and Other Drugs, 2006, Drug Trends in Sweden
- Srisurapanont M, 2001, Cochrane Database Syst Rev, 4, D003022
- Sobell LC, 1992, Measuring Alcohol Consumption, 44
- Lee MC, 1988, J Nucl Med, 29, 1207
Cited by
Courtney, K. E., & Ray, L. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.003 · Cited by 498
“The third trial found support for reduced amphetamine use and greater abstinence rates with naltrexone treatment (50 mg) in a sample of amphetamine-dependent individuals (Jayaram-Lindstrom et al., 2008).”
BackgroundLingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“One RCT reported that naltrexone (50 mg/day) significantly increased the number of amphetamine-negative urines compared with placebo (Jayaram-Lindström et al., 2008) (Ib).”
BackgroundResponding to global stimulant use: challenges and opportunities
Farrell, M., Martin, N. K., Stockings, E., Bórquez, A., Cepeda, J. A., Degenhardt, L., Ali, R., Tran, L. T., Rehm, J., Torrens, M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32230-5 · Cited by 310
Everitt, B. J. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12644 · Cited by 318
“…greater than those of naltrexone, which has been in clinical use for some years to treat alcohol dependence, and also to diminish cue-induced alcohol and cocaine craving (Volpicelli et al., 1992; Davidson et al., 1999; Palfai et al., 1999; Franck et al., 2008; Jayaram-Lindstrom et al., 2008).”
BackgroundBupropion and naltrexone in methamphetamine use disorder
Trivedi, M. H., Walker, R., Ling, W., dela Cruz, A., Sharma, G., Carmody, T., Ghitza, U. E., Wahle, A., Kim, M., Shores-Wilson, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2020214 · Cited by 281
Pharmacological approaches to methamphetamine dependence: a focused review
Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03639.x · Cited by 242
Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics
Kreek, M. J., Levran, O., Reed, B., Schlussman, S. D., Zhou, Y., & Butelman, E. R. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60390 · Cited by 220
“Of interest, naltrexone was effective in reducing use of amphetamine (another psychostimulant compound acting through the dopamine transporter) in patients without cooccurring alcoholism (36).”
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194
Konstenius, M., Jayaram‐Lindström, N., Guterstam, J., Beck, O., Philips, B., & Franck, J. (2014) · Addiction · doi:10.1111/add.12369 · Cited by 188
Self-citationMirtazapine to Reduce Methamphetamine Use: A Randomized Controlled Trial
Colfax, G. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.124 · Cited by 175
Amphetamine-group substances and HIV
Colfax, G., Santos, G.-M., Chu, P., Vittinghoff, E., Pluddemann, A., Kumar, S., & Hart, C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60753-2 · Cited by 167
Pharmacotherapy for methamphetamine/amphetamine use disorder—a systematic review and meta‐analysis
Chan, B., Freeman, M., Kondo, K., Ayers, C., Montgomery, J., Paynter, R., & Kansagara, D. (2019) · Addiction · doi:10.1111/add.14755 · Cited by 160
“4) [31 – 34] or overall use (three RCTs [31 – 33], combined RR for amphetamine-negative UDS = 1.05, 95% CI = 0.92 – 1.18; Fig.”
InfluentialHåkansson, A., & Berglund, M. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-111 · Cited by 156
“The last few years have seen emerging scientific support for naltrexone treatment in amphetamine addiction [31], although to date, no medication is formally approved for this type of addiction.”
BackgroundThe genetics of the opioid system and specific drug addictions
Levran, O., Yuferov, V. P., & Kreek, M. J. (2012) · Human Genetics · doi:10.1007/s00439-012-1172-4 · Cited by 151
“NTX also modulates amphetamine-induced effects and has a potential in the treatment of amphetamine dependence (Jayaram-Lindstrom et al. 2008a, b).”
BackgroundPharmacotherapy of amphetamine‐type stimulant dependence: An update
Brensilver, M., Heinzerling, K. G., & SHOPTAW, S. J. (2013) · Drug and Alcohol Review · doi:10.1111/dar.12048 · Cited by 140
“Following an encouraging open-label trial of naltrexone for amphetamine dependence [27], 80 treatment-seeking amphetaminedependent Swedish adults were randomised to placebo or 50 mg of naltrexone [28].”
BackgroundHeinzerling, K. G., Swanson, A.-N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.023 · Cited by 105
Meyer, J. P., Althoff, A. L., & Altice, F. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit427 · Cited by 107
“but evidence for naltrexone [25] and mirtazapine [26] treatments is emerging.”
BackgroundTsui, J. I., Mayfield, J., Speaker, E. C., Yakup, S., Ries, R. K., Funai, H., Leroux, B. G., & Merrill, J. O. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.10.005 · Cited by 105
Naltrexone Implant for the Treatment of Polydrug Dependence: A Randomized Controlled Trial
Tiihonen, J., Krupitsky, E. M., Verbitskaya, E. V., Blokhina, E. A., Mamontova, O., Föhr, J., Tuomola, P., Kuoppasalmi, K. I., Kiviniemi, V. V., & Zvartau, E. E. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11071121 · Cited by 107
Grant, J. E., Odlaug, B. L., & Kim, S. W. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.06.018 · Cited by 94
“A recent study found that the opioid antagonist naltrexone (50 mg/day) was significantly more effective than placebo at reducing cravings and drug use in subjects with amphetamine dependence (Jayaram-Lindström et al., 2008).”
BackgroundPharmacotherapy for amphetamine dependence: A systematic review
Lee, N., Jenner, L., Harney, A., & Cameron, J. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.06.038 · Cited by 87
Ray, L. A., Bujarski, S., Courtney, K. E., Moallem, N. R., Lunny, K. F., Roche, D., Leventhal, A. M., SHOPTAW, S. J., Heinzerling, K. G., London, E. D., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.83 · Cited by 84
“On balance, these results are consistent with previous work on amphetamines (Jayaram-Lindstrom et al, 2008b; Jayaram-Lindstrom et al, 2004) and cocaine (Comer et al, 2013), suggesting that NTX may have anti-craving properties and may alter subjective respones to stimulants.”
BackgroundResultNew horizons for therapeutics in drug and alcohol abuse
Jupp, B., & Lawrence, A. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.002 · Cited by 85
Intramuscular extended‐release naltrexone: current evidence
Gastfriend, D. R. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05900.x · Cited by 71
Haney, M., Ramesh, D., Glass, A., Pavlicova, M., Bedi, G., & Cooper, Z. D. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.108 · Cited by 73
Agonist Medications for the Treatment of Cocaine Use Disorder
Negus, S. S., & Henningfield, J. E. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.322 · Cited by 73
“Naltrexone also reduced amphetamine subjective effects in non-dependent and amphetamine-dependent subjects, and reduced amphetamine abuse in a placebo-controlled doubleblind clinical trial (Jayaram-Lindstrom et al, 2008a; JayaramLindstrom et al, 2008b; Jayaram-Lindstrom et al, 2004).”
BackgroundSustained release methylphenidate for the treatment of ADHD in amphetamine abusers: A pilot study
Konstenius, M., Jayaram-Lindström, N., Beck, O., & Franck, J. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.006 · Cited by 83
Self-citationTimäus, C., Meiser, M., Bandelow, B., Engel, K., Paschke, A. M., Wiltfang, J., & Wedekind, D. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2377-z · Cited by 72
Naltrexone: A Pan-Addiction Treatment?
Aboujaoude, E. N., & Salame, W. O. (2016) · CNS Drugs · doi:10.1007/s40263-016-0373-0 · Cited by 68
“2 Amphetamine-Type Substance A 2008 Swedish study [62] compared the effects of oral naltrexone and”
BackgroundBrain Mu-Opioid Receptor Binding Predicts Treatment Outcome in Cocaine-Abusing Outpatients
Ghitza, U. E., Preston, K. L., Epstein, D. H., Kuwabara, H., Endres, C. J., Bencherif, B., Boyd, S. J., Copersino, M. L., Frost, J. J., & Gorelick, D. A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.003 · Cited by 75
Injectable and implantable sustained release naltrexone in the treatment of opioid addiction
Kunøe, N., Lobmaier, P. P. K., Ngo, H., & Hulse, G. K. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12011 · Cited by 68
Miles, S. W., Sheridan, J., Russell, B., Kydd, R., Wheeler, A., Walters, C., Gamble, G., Hardley, P., Jensen, M., Kuoppasalmi, K., et al. (2013) · Addiction · doi:10.1111/add.12109 · Cited by 63
“treatment of amphetamine/methamphetamine dependence are still preliminary [11–18].”
BackgroundThe cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders
Mediouni, S., Marcondes, M. C. G., Miller, C. A., McLaughlin, J. P., & Valente, S. T. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01164 · Cited by 63
“This activity of the naltrexone had previously been observed with amphetamine and cocaine (Jayaram-Lindstrom et al., 2004, 2008a,b; Comer et al., 2013).”
BackgroundBolton, M. J., Hodkinson, A., Boda, S., Mould, A., Panagioti, M., Rhodes, S., Riste, L., & van Marwijk, H. (2019) · BMC Medicine · doi:10.1186/s12916-018-1242-0 · Cited by 68
Brown, E. S., & Gabrielson, B. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.05.006 · Cited by 58
“…positive findings with methylphenidate (Tiihonen et al., 2007), dexamphetamine (Longo et al., 2010) and naltrexone (Jayaram-Lindstrom et al., 2008a; Jayaram-Lindstrom et al., 2008b), and negative findings with modafinil (Shearer et al., 2009), bupropion (Elkashef et al., 2008) and ondansetron…”
Targeting Endogenous Mu- and Delta-Opioid Receptor Systems for the Treatment of Drug Addiction
Shippenberg, T. S., LeFevour, A., & Chefer, V. I. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708786927813 · Cited by 68
Comer, S. D., Mogali, S., Saccone, P. A., Askalsky, P., Martínez, D., Walker, E. A., Jones, J. D., Vosburg, S. K., Cooper, Z. D., Roux, P., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.143 · Cited by 56
Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonment
Kreek, M. J. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06152.x · Cited by 65
Heikkinen, M., Taipale, H. T., Tanskanen, A. J., Mittendorfer‐Rutz, E., Lähteenvuo, M., & Tiihonen, J. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.3788 · Cited by 58
Naji, L., Dennis, B. B., Rosic, T., Wiercioch, W., Paul, J., Worster, A., Thabane, L., & Samaan, Z. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109295 · Cited by 49
Naltrexone in compulsive sexual behavior disorder: a feasibility study of twenty men
Savard, J., Öberg, K. G., Chatzittofis, A., Dhejne, C., Arver, S., & Jokinen, J. (2020) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2020.04.318 · Cited by 45
Coffin, P. O., Santos, G., Hern, J., Vittinghoff, E., Santos, D., Matheson, T., Colfax, G. N., & Batki, S. L. (2017) · Addiction · doi:10.1111/add.13950 · Cited by 45
“Furthermore, our participants were actively using methamphetamine, in contrast to an earlier trial of relapse prevention among amphetamine-dependent people [28].”
BackgroundResultZhu, J., Spencer, T. J., Liu‐Chen, L., Biederman, J., & Bhide, P. G. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.015 · Cited by 47
“Previous reports have followed this line of research and found that in normal human volunteers combination of amphetamine (another stimulant that is effective as ADHD treatment and that also has significant abuse potential) and naltrexone, an opioid receptor antagonist, mitigates the subjective, positive effects (feel…”
BackgroundMethodInfluentialHåkansson, A., & Berglund, M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.03.014 · Cited by 51
NeuroHIV and Use of Addictive Substances
Chang, S. L., Connaghan, K. P., Wei, Y., & Li, M. D. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801284-0.00013-0 · Cited by 43
Endogenous opiates and behavior: 2008
Bodnar, R. J. (2009) · Peptides · doi:10.1016/j.peptides.2009.09.027 · Cited by 49
Possible role of a dysregulation of the endogenous opioid system in antisocial personality disorder
Bandelow, B., & Wedekind, D. (2015) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2497 · Cited by 41
Clinical management of psychostimulant withdrawal: review of the evidence
Li, M. J., & Shoptaw, S. J. (2023) · Addiction · doi:10.1111/add.16093 · Cited by 39
Interventions for Non-Injection Substance Use Among US Men Who Have Sex with Men: What is Needed
Santos, G., Das, M., & Colfax, G. N. (2011) · AIDS and Behavior · doi:10.1007/s10461-011-9923-0 · Cited by 41
“cation to treat alcohol dependence that in one study reduced amphetamine relapse [67].”
BackgroundThe Effects of Pharmacological Opioid Blockade on Neural Measures of Drug Cue-Reactivity in Humans
Courtney, K. E., Ghahremani, D. G., & Ray, L. A. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.99 · Cited by 39
Kohno, M., Dennis, L. E., McCready, H. D., Schwartz, D. L., Hoffman, W. F., & Korthuis, P. T. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.07.045 · Cited by 39
Stoops, W. W., & Rush, C. R. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.909283 · Cited by 35
“Naltrexone demonstrated efficacy in the human laboratory study consistent with previous findings [59,60].”
Åhman, A., Jerkeman, A., Blomé, M. A., Björkman, P., & Håkansson, A. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.03.053 · Cited by 40
Thakarar, K., Weinstein, Z., & Walley, A. Y. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2015-133720 · Cited by 34
Santos, G., Coffin, P. O., Santos, D., Huffaker, S., Matheson, T., Euren, J., DeMartini, A., Rowe, C. L., Hahn, J. A., Vlahov, D., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000922 · Cited by 37
“Although the reduction in meth use is not statistically signi fi cant in the entire sample, the numerically lower frequency of meth use in the naltrexone group is somewhat encouraging, in light of the fi ndings from another larger oral naltrexone trial by Jayaram-Lindstrom et al, 44 which observed that daily oral naltre…”
InfluentialAmphetamine Dependence and Co-Morbid Alcohol Abuse: Associations to Brain Cortical Thickness
Lawyer, G., Bjerkan, P. S., Hammarberg, A., Jayaram‐Lindström, N., Franck, J., & Agartz, I. (2010) · BMC Pharmacology · doi:10.1186/1471-2210-10-5 · Cited by 37
Self-citationRoche, D. J. O., Worley, M. J., Courtney, K. E., Bujarski, S., London, E. D., SHOPTAW, S. J., & Ray, L. A. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4607-8 · Cited by 34
“…treatment reduced amphetamine use and produced greater abstinence rates compared with placebo in a sample of amphetamine-dependent individuals (Jayaram-Lindström et al. 2008a), although a smaller combined pharmacotherapy study did not replicate these results in MA users (Grant et al. 2010).”
ResultAdvances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction
Cao, D.-N., Shi, J.-J., Hao, W., Wu, N., & Li, J. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.03.040 · Cited by 34
Stoops, W. W., Pike, E., Hays, L. R., Glaser, P. E. A., & Rush, C. R. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.11.018 · Cited by 32
“…have demonstrated superiority to placebo for reducing amphetamine use in some patients, although neither of these medications completely eliminates drug taking when tested in randomized, doubleblind, clinical trials (Jayaram-Lindström et al., 2008a; Elkashef et al., 2008; Shoptaw et al., 2008).”
BackgroundMethodInfluentialMedications for substance use disorders (SUD): emerging approaches
Butelman, E. R., & Kreek, M. J. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1395855 · Cited by 33
“Some studies have shown that oral naltrexone can decrease some effects of amphetamine, methamphetamine, or cocaine [99,108,109].”
BackgroundOutcome Measures in Medication Trials for Substance Use Disorders
McCann, D. J., Ramey, T., & Skolnick, P. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0038-5 · Cited by 33
Effects of amphetamine on the human brain opioid system – a positron emission tomography study
Guterstam, J., Jayaram‐Lindström, N., Červenka, S., Frost, J. J., Farde, L., Halldin, C., & Franck, J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000818 · Cited by 36
“The order of amphetamine and placebo was double-blinded and randomized.”
Self-citationMobile alcohol biosensors and pharmacotherapy development research
Roberts, W., & McKee, S. A. (2018) · Alcohol · doi:10.1016/j.alcohol.2018.07.012 · Cited by 32
The Effect of Buprenorphine on Methamphetamine Cravings
Salehi, M., Emadossadat, A., Kheirabadi, G. R., Maracy, M. R., & Maracy, M. R. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000408 · Cited by 31
Ruiz, M. A., Skeem, J. L., Poythress, N. G., Douglas, K. S., & Lilienfeld, S. O. (2010) · International Journal of Forensic Mental Health · doi:10.1080/14999013.2010.517258 · Cited by 31
Rúnarsdóttir, V. Á., Hansdóttir, I., Tyrfingsson, Þ., Einarsson, M., Dugosh, K. L., Royer-Malvestuto, C., Pettinati, H. M., Khalsa, J. H., & WOODY, G. E. (2017) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000297 · Cited by 27
“In clinical studies (Jayaram-Lindstrom et al., 2004, 2005, 2007, 2007, 2008) found that naltrexone reduced amphetamine-reinforcing effects in healthy volunteers was well tolerated by amphetamine-dependent patients seeking treatment and blocked amphetamine-induced craving in detoxified…”
Pharmacotherapy treatment of stimulant use disorder
Liu, M. T. (2021) · Mental Health Clinician · doi:10.9740/mhc.2021.11.347 · Cited by 26
“05).(38) Two RCTs(39,40) on naltrexone extended-release injection (380 mg every 4 weeks) and 1 RCT on naltrexone implants (1000 mg every 10 weeks) showed no difference in methamphetamine use, abstinence, or treatment retention.”
BackgroundMooney, L. J., Hillhouse, M. P., Thomas, C., Ang, A., Sharma, G., Terry, G., Chang, L., Walker, R., Trivedi, M., Croteau, D., et al. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000218 · Cited by 25
“…predicated on their potentially complementary effects as shown in clinical research and as postulated in mechanistic arguments for naltrexone (eg, Jayaram-Lindström et al., 2008b), for bupropion (eg, Ascher et al., 1995; Newton et al., 2006), and for the combination, which could regulate the…”
BackgroundNaltrexone attenuates amphetamine-induced locomotor sensitization in the rat
Häggkvist, J., Björkholm, C., Steensland, P., Lindholm, S., Franck, J., & Schilström, B. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2009.00199.x · Cited by 27
“…craving and the propensity to relapse in amphetamine-dependent patients (JayaramLindström et al. 2005, 2008a) and reduces the subjective effects induced by a priming dose of amphetamine, both in healthy volunteers and in patients with amphetamine dependence (Jayaram-Lindström et al. 2004, 2008b).”
BackgroundResultSelf-citationHäggkvist, J., Lindholm, S., & Franck, J. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2009.00150.x · Cited by 27
Self-citationMarks, K. R., Lile, J. A., Stoops, W. W., & Rush, C. R. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3449-x · Cited by 25
“…naltrexone to attenuate the effects of d-amphetamine (i.e., healthy participants, Jayaram-Lindström et al. 2004; amphetaminedependent individuals, Jayaram-Lindström et al. 2008b), damphetamine (10 and 20 mg) did not produce sufficient positive subjective effects to determine the impact of…”
InfluentialLin, S. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12163 · Cited by 23
Enkephalin as a Pivotal Player in Neuroadaptations Related to Psychostimulant Addiction
Mongi‐Bragato, B., Avalos, M. P., Guzman, A. S., Bollati, F. A., & Cancela, L. M. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00222 · Cited by 22
“Morever, naltrexone did significantly reduce craving for cocaine and tobacco during cocaine sessions (146) as well as amphetamine craving (149, 150).”
BackgroundInfluentialClinical Neuroscience of Addiction: Similarities and Differences Between Alcohol and Other Drugs
Karoly, H. C., YorkWilliams, S. L., & Hutchison, K. E. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12884 · Cited by 23
Marks, K. R., Lile, J. A., Stoops, W. W., Glaser, P. E. A., Hays, L. R., & Rush, C. R. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000488 · Cited by 19
“However, the present results are in agreement with larger clinical trials that demonstrated a reduction in amphetamine-positive urine samples during naltrexone treatment relative to placebo.(64,65) Naltrexone did not alter self-administration of 30-mg methamphetamine, however, indicating that the ability of naltrexone…”
ResultEastwood, E., & Phillips, T. J. (2013) · Genes Brain & Behavior · doi:10.1111/gbb.12100 · Cited by 19
“The MOP-r antagonist naltrexone (NTX) reduced MA intake in self-administering rhesus macaques and reduced the subjective effects of MA in human-dependent users (Jayaram-Lindstrom et al. 2004, 2008a,b).”
Jayaram‐Lindström, N., Guterstam, J., Häggkvist, J., Ericson, M., Malmlöf, T., Schilström, B., Halldin, C., Červenka, S., Saijo, T., Nordström, A., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.79 · Cited by 19
Self-citationControlled delivery of naltrexone by an intraoral device: In vivo study on human subjects
Paderni, C., Campisi, G., Schumacher, A., Göttsche, T., Giannola, L. I., De, V., & Wolff, Ä. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.04.070 · Cited by 18
“In amphetamine dependence, reduced craving during NLX treatment has recently been reported (Jayaram-Lindstrom et al., 2008).”
BackgroundHamel, C., Corace, K., Hersi, M., Rice, D., Willows, M., Macpherson, P., Sproule, B., Flores-Aranda, J., Garber, G., Esmaeilisaraji, L., et al. (2020) · Systematic Reviews · doi:10.1186/s13643-020-01499-z · Cited by 17
“, naltrexone [84, 85]), antidepressants [6, 31, 86]”
Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients
Timäus, C., Meiser, M., Wiltfang, J., Bandelow, B., & Wedekind, D. (2021) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2800 · Cited by 17
The Globalization of Addiction Research
Rawson, R. A., WOODY, G. E., Kresina, T. F., & Gust, S. W. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000067 · Cited by 17
“A study in Sweden reported that naltrexone might be useful for treating amphetamine dependence.(58) To extend the Swedish finding, NIDA funded a study in Iceland led by researchers at the University of Pennsylvania and the SAA– National Center of Addiction Medicine and Vogur Hospital in Reykjavik.”
BackgroundImmunopharmacotherapeutic advancements in addressing methamphetamine abuse
Lee, J. C., & Janda, K. D. (2020) · RSC Chemical Biology · doi:10.1039/d0cb00165a · Cited by 15
Integrative Pharmacology in the Treatment of Substance Use Disorders
Donlon, J., Kumari, P., Varghese, S. P., Bai, M. Y., Florentin, O. D., Frost, E. D., Banks, J., Vadlapatla, N., Kam, O., Shad, M. U., et al. (2023) · Journal of Dual Diagnosis · doi:10.1080/15504263.2023.2293854 · Cited by 17
Clinical neuroscience of amphetamine-type stimulants
Courtney, K. E., & Ray, L. A. (2015) · Progress in brain research · doi:10.1016/bs.pbr.2015.07.010 · Cited by 17
“…an opioid antagonist with greatest affinity for the m- and k-opioid receptors in humans (Emmerson et al., 1994; Toll et al., 1998), has been associated with reduced amphetamine use and greater abstinence rates in a sample of amphetamine-dependent individuals ( Jayaram-Lindstrom et al., 2008).”
BackgroundLi, M. J., Chau, B., Belin, T. R., Carmody, T. J., Jha, M. K., Marino, E. N., Trivedi, M. H., & SHOPTAW, S. J. (2024) · Addiction · doi:10.1111/add.16529 · Cited by 14
“Separately, NTX [3, 4] and BUPN [5 – 7] have shown some efficacy for treating MA use disorder.”
BackgroundAdvances in Opioid Antagonist Treatment for Opioid Addiction
Ling, W. W., Mooney, L. J., & Wu, L.-T. T. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.03.002 · Cited by 15
Effect of opioid antagonists on sex hormone secretion.
Tenhola, H., Sinclair, D., Alho, H., & Lahti, T. A. (2012) · PubMed · doi:10.3275/8181 · Cited by 14
Epidemiological trends and the advances of treatments of amphetamine‐type stimulants (ATS) in China
Sun, H., Chen, H., Yang, F., Lü, L., & Kosten, T. R. (2014) · American Journal on Addictions · doi:10.1111/j.1521-0391.2014.12116.x · Cited by 14
Pharmacotherapy for Stimulant-Related Disorders
Haile, C. N., & Kosten, T. R. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0415-y · Cited by 13
“Results revealed that participants treated with naltrexone presented significantly lower numbers of AMPH-positive urines and reported less craving for AMPH compared to placebo [109].”
Hambuchen, M. D., Rüedi‐Bettschen, D., Williams, D. K., Hendrickson, H. P., & Owens, S. M. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.09.025 · Cited by 13
Pal, R., Mendelson, J. E., Flower, K., Garrison, K. J., Yount, G. L., Coyle, J., & Galloway, G. P. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000107 · Cited by 14
“A small placebo-controlled randomized clinical trial demonstrated the efficacy of naltrexone in reducing amphetamine use in amphetamine-dependent individuals (Jayaram-Lindstrom et al., 2008a).”
BackgroundMethodResultCue reactivity and opioid blockade in amphetamine dependence: A randomized, controlled fMRI study
Guterstam, J., Jayaram‐Lindström, N., Berrebi, J., Petrović, P., Ingvar, M., Fransson, P., & Franck, J. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.06.023 · Cited by 13
Self-citationAntagonist Models for Treating Persons With Substance use Disorders
WOODY, G. E. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0489-1 · Cited by 11
Preclinical evidence of new opioid modulators for the treatment of addiction
Rodríguez‐Arias, M., Aguilar, M. A., Manzanedo, C., & Miñarro, J. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.500612 · Cited by 12
“MOPR antagonism has been shown to attenuate the behavioral and neurochemical effects of amphetamine in humans [22] and rodents.”
BackgroundMaintenance on naltrexone + amphetamine decreases cocaine-vs.-food choice in male rhesus monkeys
Moerke, M. J., Banks, M. L., Cheng, K., Rice, K. C., & Negus, S. S. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.09.020 · Cited by 10
“…naltrexone decreased amphetamine self-administration in rhesus monkeys (Jimenez-Gomez et al., 2011), methamphetamine self-administration in a human laboratory study (Marks et al., 2016) and amphetamine use by patients meeting criteria for amphetamine dependence (Jayaram-Lindstrom et al., 2008).”
BackgroundVerification of a genetic locus for methamphetamine intake and the impact of morphine
Eastwood, E., Eshleman, A. J., Janowsky, A. J., & Phillips, T. J. (2017) · Mammalian Genome · doi:10.1007/s00335-017-9724-5 · Cited by 10
Elmosalamy, A., Sirohi, A., Moustafa, A., Masoud, O., Hassett, L. C., Kolla, B. P., & Singh, B. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112789 · Cited by 11
(SPNS), G. D. E. D. L. S. D. P. N. S. E. S., (SEP), S. E. D. P., (GESIDA), G. D. E. D. S., & (SEIP), S. E. D. I. P. (2015) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2015.07.018 · Cited by 13
Ghasemi, A., Chehregosha, M., Dastoorpoor, M., kolsoumTomaj, O., Farizi, M., Aghababaeian, H., Jamshidi, E., Khanjani, N., & Kouhpayeh, S. A. (2018) · Mental Health & Prevention · doi:10.1016/j.mhp.2018.07.002 · Cited by 10
Naltrexone maintenance fails to alter amphetamine effects on intracranial self-stimulation in rats.
Sakloth, F., & Negus, S. S. (2018) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000183 · Cited by 8
Metadata
- Authors
- Jayaram-Lindström, N., Hammarberg, A., Beck, O., & Franck, J.
- Venue
- American Journal of Psychiatry
- Published
- 2008-11
- Volume
- 165
- Issue
- 11
- Pages
- 1442-1448
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2116763568
- Cited by
- 185
- References
- 26
- Citations by year
- 2025: 11 · 2024: 8 · 2023: 6 · 2022: 8 · 2021: 6 · 2020: 12 · 2019: 5 · 2018: 11 · 2017: 11 · 2016: 9 · 2015: 17 · 2014: 18 · 2013: 15 · 2012: 16
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- naltrexone, amphetamine dependence, pharmacotherapy, relapse prevention, abstinence, craving, urine drug testing, medication adherence
- MeSH terms
- Adult, Amphetamine, Double-Blind Method, Female, Humans, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Substance Withdrawal Syndrome, Substance Abuse Detection, Survival Analysis, Treatment Outcome, Amphetamine-Related Disorders, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.